HIMS Stock Price Today (September 2026) — Hims & Hers Health, Inc. Analysis & Key Metrics 2026-09-03
Hims & Hers Health, Inc. (HIMS) is trading at $27.82, down 3.00% today (as of September 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $31.23 (12.3% upside).
- Volatility remains elevated (80.58% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (38.20% YoY) alongside significant competitive pressures.
HIMS Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Hims & Hers Health, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $7.43B
P/E Ratio
Forward P/E: 29.51
Revenue Growth
Year over Year
Analyst Target
+12.3% upside potential
Key Investor Questions About HIMS
What investors need to know before buying
Based on current market data, HIMS presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 41.70)
- Fundamentals say: Caution warranted (high leverage concerns)
HIMS's growth trajectory depends on its ability to expand within the Drug Manufacturers - Specialty & Generic sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - Specialty & Generic operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for HIMS investors include debt exposure and competitive dynamics in the Drug Manufacturers - Specialty & Generic industry.
- $1.55B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - Specialty & Generic.
52-Week Trading Range
Over the past year, HIMS stock traded between $13.74 and $65.30—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 80.58% annualized volatility and β=2.22, the stock exhibits high sensitivity to market moves—making HIMS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Reasons to Retain Hims & Hers Stock in Your Portfolio for Now
HIMS has entered the second half of 2026 with weight-loss, international and AI momentum, but margin pressure and FDA uncertainty remain.
HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.
HIMS Stock Kicks Off September In The Red: FDA’s GLP-1 Alert Steals The Spotlight From Australia Expansion
The FDA reported more than 1,700 adverse events involving compounded Semaglutide and Tirzepatide
Hims & Hers falls after FDA crackdown on unapproved weight-loss drugs
Hims & Hers Health (NYSE:HIMS) shares fell 3.2% after the FDA warned telehealth companies and compounding pharmacies over unapproved weight-loss drugs, including versions of semaglutide, tirzepatide and retatrutide. The agency said retatrutide and cagrilintide cannot legally be used in...
Hims & Hers’ Australia Expansion Adds Growth, But Execution Will Be Key
Hims & Hers Health, Inc. (NYSE:HIMS) has entered Australia, marking its first expansion into the Asia-Pacific market. The move follows its acquisition of Australian digital-health platform Eucalyptus, which includes men’s health brand Pilot and women’s health brand Juniper. Hims is initially rolling out weight-loss and men’s health treatments, with plans to introduce women’s health services […]
Market Shocks Are Not Where Hims & Hers Health Stock Has Fallen Furthest
Its deepest fall inside a market shock is not its deepest fall, and that gap is what a holder should size for.
Hims & Hers Health (HIMS) Stock Looks Like A Bargain On Sales But Mixed On Broader Checks
Hims & Hers Health stock has surged over the last three years, yet recent share price setbacks and a mixed valuation score leave investors weighing how much of the story is already reflected in the current price. The stock is up about 3.2x over the past three years. That puts extra focus on whether that strong run can be supported by future business performance. Plans to expand into experimental peptide therapies may support higher long term growth expectations. At the same time, regulatory...
MarketBeat Week in Review – 08/24 - 08/28
MarketBeat analysts recap a mixed earnings week, covering AI infrastructure demand, retail's K-shaped consumer trends, Meta's $18 billion settlement, and stock picks across tech, biotech, and retail sectors.
Hims & Hers Health (HIMS) Is Down 14.6% After Raising Guidance Amid Privacy Scrutiny - What's Changed
Earlier this week, Hims & Hers Health reported quarterly revenue of US$753.2 million, up 38.2% year on year, added 307,000 customers to reach 2.89 million, and raised both next-quarter revenue guidance and full-year EBITDA guidance above analyst expectations. Alongside these financial updates, new survey findings on Gen Z sexual health attitudes and ongoing regulatory and legal scrutiny of Hims & Hers’ privacy and billing practices highlight both expanding demand for its services and...
Hims & Hers (HIMS) CEO Says the FTC Doesn’t Understand His Own Company
On August 18, 2026, Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum told CNBC that a Federal Trade Commission lawsuit over the company’s data-sharing and subscription practices “misunderstands how the company works.” He defended the company’s compounded GLP-1 drug sales as having helped lower prices for weight-loss treatments. Why This Matters Hims & Hers […]
Explore More Analysis for HIMS
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Hims & Hers Health, Inc.
Hims & Hers Health, Inc. (HIMS) is currently trading at $27.82. The RSI (14-day) is at 41.7, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $31.23 implies 12.3% upside from current levels. Volatility is high at 80.6% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Hims & Hers Health, Inc. (HIMS): The trailing P/E ratio is -43.47, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 29.51. The PEG ratio is 2.15, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 20.03. Price-to-Sales is 2.43. Valuation should be compared to Drug Manufacturers - Specialty & Generic industry peers for context, as different sectors trade at different multiples.
Based on 13 analysts covering HIMS, the consensus price target is $31.23. This represents a 12.3% upside from the current price of $27.82. The range spans from a low target of $23.00 to a high target of $42.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Hims & Hers Health, Inc. (HIMS) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Hims & Hers Health, Inc. (HIMS) investors include: 1. High volatility (80.6% annualized)—the stock can experience significant daily price swings. 2. Elevated debt levels (D/E ratio of 477.13) which could pressure margins in a rising rate environment. 3. Elevated short interest (30.2% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Drug Manufacturers - Specialty & Generic sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Hims & Hers Health, Inc.'s (HIMS) current debt and financial health profile: Total debt stands at $1.55B. The debt-to-equity ratio is 477.13, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 0.93, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.82. The company holds $841.05M in cash and equivalents. Free cash flow is positive at $849.44M, providing a cushion for debt servicing and shareholder returns.